Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/OTT.S98242 http://scihub22266oqcxt.onion/10.2147/OTT.S98242 C4789847!4789847!27022278     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Onco+Targets+Ther 2016 ; 9 (ä): 1181-8 Nephropedia Template TP {{tp|p=27022278|t=2016. Profile of farletuzumab and its potential in the treatment of solid tumors |pdf=|usr=}}{{27022278}} gab.com Text Profile of farletuzumab and its potential in the treatment of solid tumors JO: Onco Targets Ther http://www.kidney.de/pget.php?&tw=1&pmid=27022278 #FOAvip Folate receptor (FR) ? expression in normal tissues is restricted to a subpopulation of epithelial cells. In contrast, FR? is overexpressed in epithelial ovarian cancer (EOC) and non-small-cell lung carcinoma. Therefore, FR? is considered a promising therapeutic target for EOC and non-small-cell lung carcinoma. Farletuzumab (MORAb-003) is a humanized monoclonal antibody of immunoglobulin G subtype 1 kappa, targeting human FR?. To date, Phase I/II clinical trials have clearly demonstrated the feasibility and safety of farletuzumab as a treatment option against solid tumors. However, in Phase III clinical trial that was conducted to verify the combined effect of paclitaxel?carboplatin combination therapy and farletuzumab for patients with recurrent EOC, improvement in progression-free survival was not statistically significant. This result might be owing to the fact that the eligibility criteria for these studies did not include FR? expression. The significance of FR? as a predictive/prognostic biomarker remains unclear. In addition, there is currently no established biomarker to predict the response and toxicities among patients receiving farletuzumab therapy. Furthermore, the primary mechanism of action of farletuzumab has not yet been identified. Therefore, further research to identify the mechanism of farletuzumab in tumor suppression is necessary to clarify the full potential of this chemotherapeutic agent. Twit Text FOAVip Profile of farletuzumab and its potential in the treatment of solid tumors ????Onco Targets Ther http://www.kidney.de/pget.php?&tw=1&pmid=27022278 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27022278 #FOAvip English Wikipedia <ref>{{Cite pmid|27022278}}</ref> Profile of farletuzumab and its potential in the treatment of solid tumors #MMPMID27022278 Sato S; Itamochi H Onco Targets Ther 2016[]; 9 (ä): 1181-8 PMID27022278show ga Folate receptor (FR) ? expression in normal tissues is restricted to a subpopulation of epithelial cells. In contrast, FR? is overexpressed in epithelial ovarian cancer (EOC) and non-small-cell lung carcinoma. Therefore, FR? is considered a promising therapeutic target for EOC and non-small-cell lung carcinoma. Farletuzumab (MORAb-003) is a humanized monoclonal antibody of immunoglobulin G subtype 1 kappa, targeting human FR?. To date, Phase I/II clinical trials have clearly demonstrated the feasibility and safety of farletuzumab as a treatment option against solid tumors. However, in Phase III clinical trial that was conducted to verify the combined effect of paclitaxel?carboplatin combination therapy and farletuzumab for patients with recurrent EOC, improvement in progression-free survival was not statistically significant. This result might be owing to the fact that the eligibility criteria for these studies did not include FR? expression. The significance of FR? as a predictive/prognostic biomarker remains unclear. In addition, there is currently no established biomarker to predict the response and toxicities among patients receiving farletuzumab therapy. Furthermore, the primary mechanism of action of farletuzumab has not yet been identified. Therefore, further research to identify the mechanism of farletuzumab in tumor suppression is necessary to clarify the full potential of this chemotherapeutic agent. äProfile of farletuzumab and its potential in the treatment of solid tu(epmc).pdf DeepDyve Pubget Overpricing